Michael Penlington - Impact of AI and New Standards in Clinical Trials

AI Uncovered

We welcome Michael Penlington to AI Uncovered. Michael has been working in Pharma for his entire career including roles in leading development of Vaccines and Clinical reporting at Novartis, as well as Senior Director roles of Science writing, Global Medical Writing and Medical Writing Center of Excellence at GSK.
Most recently, Michael has taken on a new challenge as Director of Digital Clinical Development Solutions at Nurocor.
In this episode, Tim and Michael discuss digital transformation in the pharmaceutical industry, with a particular focus on the role of AI in clinical development. They delve into the current trends, challenges and the driving forces behind this digital revolution in pharma. Michael shares insights from his extensive career, including his experience in medical writing and as a Director of Digital Clinical Development Solutions. He also provides insights on the impact of new standards like ICH M11 on study design, clinical trial management and data management, offering a glimpse into what the future holds for clinical processes. Michael is deeply engaged in the intersection of digital technology and life sciences, making him a leading voice in this transformative era for pharma.

Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.

With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization.

Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.